title: The decision-making process and criteria in selecting candidate drugs for progeria clinical trials.
authors.affiliation: Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA Department of Pediatrics, Hasbro Children's Hospital and Warren Alpert Medical School of Brown University, Providence, RI, USA.
authors.forename: Leslie B
authors.identifier: 0000-0002-4353-2520
authors.initials: LB
authors.lastname: Gordon
authors.affiliation: Dana-Farber Boston Children's Cancer and Blood Disorder Center, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Mark W
authors.initials: MW
authors.lastname: Kieran
authors.affiliation: Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
authors.forename: Monica E
authors.initials: ME
authors.lastname: Kleinman
authors.affiliation: National Cancer Institute, NIH, Bethesda, MD, USA.
authors.forename: Tom
authors.initials: T
authors.lastname: Misteli
mesh_terms: D002648:Child; D000066491:Clinical Decision-Making / Q000379:methods; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000379:methods; D006801:Humans; D034904:Lamin Type A / Q000235:genetics; D011371:Progeria / Q000188:drug therapy* / Q000235:genetics; D035583:Rare Diseases / Q000188:drug therapy / Q000235:genetics
chemical_list: D034904:Lamin Type A